Skip to main content

Phase II study of petosemtamab and pembrolizumab for recurrent/metastatic HNSCC



Jerome Fayette, MD, Centre Lèon Bèrard, Lyon, France, shares insight into the results of a Phase II trial (NCT03526835), …

source

Leave a Reply

Your email address will not be published. Required fields are marked *